A little over a month after its debut as a public company, Seattle-based Adaptive Biotechnologies Inc. reported second-quarter results. The company saw revenues of $22.1 million, which topped William Blair estimates, as well as the consensus of $19.4 million.
A little over a month after its debut as a public company, Seattle-based Adaptive Biotechnologies Inc. reported second-quarter results. The company saw revenues of $22.1 million, which topped William Blair estimates, as well as the consensus of $19.4 million.
Saluda Medical Pty. Ltd. has had a busy summer. First, it revealed results from two clinical studies evaluating its Evoke ECAP-controlled closed-loop spinal cord stimulation system and its impact on those suffering from chronic pain. It subsequently won some backing from two major medical device players: Marlborough, Mass.-based Boston Scientific Corp. and Medtronic plc, of Dublin.
Endologix Inc., of Irvine, Calif., reported revenues in-line with expectations Thursday, as it discussed pipeline progress and a new agreement with Boston Scientific for China.
Sean Lavin, analyst at BTIG, pointed to how the company has controlled expenses and maintained guidance as positives. "We maintain our Buy and applaud the progress made this quarter," Lavin wrote.
San Clemente, Calif.-based Glaukos Corp., an ophthalmic medical technology and pharmaceutical company that focuses on glaucoma, corneal disorders and retinal diseases, has agreed to buy Avedro Inc. in an all-stock transaction.
Exo Imaging Inc., a Redwood City, Calif.-based company focusing on an ultrasound platform that is based on patented piezoelectric micromachined ultrasonic transducers technology and artificial intelligence (AI), has scored $35 million in a series B round.
